Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: Results from a population-based study using the PROFILES registry

European Journal of Haematology

Volumn 89, Issue 4, 2012, Pages 311-319

  Mols, Floortje ^a,b   Oerlemans, Simone ^a,b   Vos, Allert H ^c   Koster, Ad ^d   Verelst, Silvia ^e   Sonneveld, Pieter ^e   Van de Poll Franse, Lonneke V ^a,b  

^a TILBURG UNIVERSITY   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c BERNHOVEN HOSPITAL   (Netherlands)

^d Department of Gynecology   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Disease specific complaints; Multiple myeloma; Quality of life; Side effects; Symptoms

Indexed keywords

ADULT; AGED; ANOREXIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; BONE MARROW TRANSPLANTATION; BONE PAIN; CANCER REGISTRY; CONSTIPATION; DIARRHEA; DISEASE COURSE; DROWSINESS; DYSPNEA; FATIGUE; FEAR; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NAUSEA; PAIN; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SHOULDER PAIN; SLEEP DISORDER; SYMPTOM; TREATMENT RESPONSE; VOMITING;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POPULATION SURVEILLANCE; QUALITY OF LIFE; REGISTRIES;

EID: 84866353022     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01831.x     Document Type: Article

References (31)

1. Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E. Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 2010;46:160-9.
2. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-83.
3. Jagannath S. Treatment of myeloma in patients not eligible for transplantation. Curr Treat Options Oncol 2005;6:241-53.
4. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-6.
5. Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F. Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol 2009;83:279-89.
6. Uyl-de Groot CA, Buijt I, Gloudemans IJ, Ossenkoppele GJ, Berg HP, Huijgens PC. Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol 2005;74:136-43.
7. Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant 2009;15:12-20.
8. Verelst SG, Termorshuizen F, Uyl-de Groot CA, et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol 2011;90:1427-39.
9. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205-12.
10. Lee SJ, Richardson PG, Sonneveld P, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 2008;143:511-9.
11. Sirohi B, Powles R, Lawrence D, Treleaven J, Kulkarni S, Leary A, Rudin C, Horton C, Morgan G. An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b. Ann Oncol 2007;18:1388-94.
12. Gulbrandsen N, Hjermstad MJ, Wisloff F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004;72:172-80.
13. Larsen J, Nordstrom G, Bjorkstrand B, Ljungman P, Gardulf A. Symptom distress, functional status and health-related quality of life before high-dose chemotherapy with stem-cell transplantation. Eur J Cancer Care (Engl). 2003;12:71-80.
14. Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psychooncology 2011;20:88-97.
15. Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43:1670-8.
16. Janssen-Heijnen MLG, Louwman WJ, Van de Poll-Franse LV, Coebergh JWW. Results of 50 Years Cancer Registry in the South of the Netherlands: 1955-2004 (in Dutch). Eindhoven: Eindhoven Cancer Registry, 2005.
17. van de Poll-Franse LV, Horevoorts N, Eenbergen MV, et al. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: Scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 2011;47:2188-94.
18. van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM, Taphoorn MJ, Aaronson NK. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 2010;47:667-75.
19. UICC. TNM Atlas Illustrated Guide to the TNM/PTNM Classification of Malignant Tumors. 4th edn, 2nd Revision ed. Berlin: Springer-Verlag, 1992. p. 141-4.
20. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156-63.
21. van Duijn C, Keij I. Sociaal-economische status indicator op postcode niveau. Maandstatistiek van de bevolking 2002;50:32-5.
22. Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res 1993;2:319-25.
23. Fayers P, Aaronson NK, Bjordal K, Group. ObotEQoL. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: EORTC, 2001.
24. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 2011;29:89-96.
25. Kvam AK, Fayers P, Wisloff F. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study Eur J Haematol 2010;84:345-53.
26. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
27. Snowden JA, Ahmedzai SH, Ashcroft J, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011;154:76-103.
28. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010;51:1178-87.
29. Ludwig H, Zojer N. Supportive care in multiple myeloma. Best Pract Res Clin Haematol 2007;20:817-35.
30. Booker R, Olson K, Pilarski LM, Noon JP, Bahlis NJ. The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma. Oncol Nurs Forum 2009;36:209-16.
31. Terpos E, Cibeira MT, Blade J, Ludwig H. Management of complications in multiple myeloma. Semin Hematol 2009;46:176-89.